News around the biocity campus

RIBOLUTION Health GmbH founded in Leipzig

Fraunhofer IZI. The new biotech start-up in Leipzig, Germany, aims to improve diagnosis and therapy of complex diseases such as cancer, chronic inflammatory and infectious diseases. First planned products are tests for diagnosis and prognosis of prostate cancer that offer higher accuracy compared to conventional processes.

The foundation for the successful development of the newly formed enterprise is a comprehensive, interdisciplinary biomarker platform which was developed in collaboration with five Fraunhofer institutes over the past five years. Through the RIBOLUTION Project (“RIBOnucleic acid-based diagnostic soLUTIONs”), funded by the Fraunhofer-Zukunftsstiftung (Fraunhofer Future Foundation), non-coding ribonucleic acids (“ncRNAs”) were identified as the source for novel biomarkers for a variety of diseases.

Highly specific biomarkers are the prerequisite for the development of a new generation of diagnostic tests with improved performance in comparison to existing procedures. As a result of the work performed within the RIBOLUTION Project, various promising biomarker candidates for the diagnosis and prognosis of prostate cancer were discovered and successfully tested on over 250 patients in collaboration with the Dresden University of Technology. Further biomarker programs in the fields of cancer, chronic inflammatory and infectious diseases are in earlier stages of development.

“The close collaboration between Fraunhofer and the newly founded company will provide us with outstanding perspectives to play a leading role in the rapidly expanding market for so-called “Next Generation Diagnostics,” explains Dr. Christoph Sachsenmaier, Managing Director of RIBOLUTION Health GmbH.

“The results of our studies were so promising that the commercialization through the new company was the next logical step for us,” explains Professor Friedemann Horn of the University of Leipzig’s Faculty of Medicine, and coordinator of the RIBOLUTION Project.

“The ncRNA biomarkers that we identified represent a clinically highly relevant class of substances which can now be implemented in diagnostic and therapeutic processes,” states Professor Manfred Wirth of the Dresden University Hospital, who previously brought his clinical expertise to the research project and now to the new company.

Market launch of the first products for diagnosis and prognosis of prostate cancer are planned for the end of 2017.

RIBOLUTION Health GmbH founded in Leipzig

Previous News

Major progress on global biodiversity observation system

iDiv Leipzig. iDiv hosted a three day workshop where scientists and technical and legal experts made great steps towards the development of a cooperative and global monitoring system for changes in biodiversity. The workshop, which was a breakthrough in global collaboration, was organized for the first time as part of the EU horizon 2020 project GLOBIS-B, coordinated by the University of Amsterdam. […]

Next News

2016 Breakthrough Prize in Life Sciences for Svante Pääbo

Max Planck Institute. Sequencing of ancient DNA and genomes honoured as scientific breakthrough

One of the 2016 Breakthrough Prizes in Life Sciences was bestowed to Max Planck director Svante Pääbo for pioneering the sequencing of ancient DNA and ancient genomes, thereby illuminating the origins of modern humans, our relationships to extinct relatives such as Neanderthals, and the evolution of human populations and traits. The seven prizes, each endowed with 3 Million US dollars, were awarded on 8 November in Silicon Valley, USA. […]